Atrion Co. (NASDAQ:ATRI) Stake Raised by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC grew its holdings in shares of Atrion Co. (NASDAQ:ATRI) by 1.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 205,393 shares of the medical instruments supplier’s stock after purchasing an additional 2,111 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned approximately 11.67% of Atrion worth $92,926,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Atrion by 0.4% during the first quarter. Vanguard Group Inc. now owns 84,876 shares of the medical instruments supplier’s stock valued at $39,344,000 after purchasing an additional 326 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Atrion by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 14,921 shares of the medical instruments supplier’s stock valued at $6,751,000 after acquiring an additional 436 shares during the last quarter. Versor Investments LP bought a new stake in shares of Atrion during the 2nd quarter worth $3,247,000. Penn Mutual Asset Management LLC acquired a new position in shares of Atrion in the 4th quarter worth $1,949,000. Finally, Envestnet Asset Management Inc. raised its position in shares of Atrion by 27.1% during the second quarter. Envestnet Asset Management Inc. now owns 4,986 shares of the medical instruments supplier’s stock worth $2,256,000 after purchasing an additional 1,063 shares during the period. Institutional investors own 66.19% of the company’s stock.

Atrion Price Performance

Shares of ATRI opened at $459.92 on Friday. The company has a 50-day moving average of $458.99 and a two-hundred day moving average of $445.26. The stock has a market cap of $809.46 million, a price-to-earnings ratio of 43.23 and a beta of 0.69. Atrion Co. has a one year low of $274.98 and a one year high of $503.24.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.23 EPS for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The firm had revenue of $48.77 million during the quarter.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Atrion in a research report on Thursday. They issued a “sell” rating for the company.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.